Clicky

Amneal Pharmaceuticals, Inc.(AMRX)

Description: Amneal Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. It operates in two segments, which include Impax Generics and Impax Specialty Pharma. The Impax Generics is focused on the development, manufacture, sale and distribution of the Company's generic products, which are the pharmaceutical and therapeutic equivalents of brand-name drug products and are marketed under their drug names. The Impax Specialty Pharma is engaged in the promotion, sale and distribution of several branded products, including its branded pharmaceutical product, Rytary, an extended release oral capsule formulation of carbidopa-levodopa for the treatment of Parkinson's disease (PD), post-encephalitic Parkinsonism and Parkinsonism, and Zomig (zolmitriptan) products, indicated for the treatment of migraine headaches.


Keywords: Pharmaceutical Pharmaceutical Products Drugs Health Sciences Parkinson's Disease Migraine Treatment Of Parkinson's Disease Drug Products Generic Drug Headache Treatment Of Migraine L Dopa Generic Products Carbidopa Migraine Headache Migraine Headaches

Home Page: www.amneal.com

AMRX Technical Analysis

400 Crossing Boulevard
Bridgewater, NJ 08807
United States
Phone: 908 947 3120


Officers

Name Title
Mr. Chirag K. Patel Co-Founder, Co-CEO, Pres & Director
Mr. Chintu Patel R.Ph, R.Ph. Co-Founder, Co-CEO & Director
Mr. Anastasios G. Konidaris Exec. VP & CFO
Ms. Nikita Shah Exec. VP and Chief HR & Strategic Planning Officer
Mr. Andrew S. Boyer Exec. VP & Chief Commercial Officer of Generics
Mr. Anthony DiMeo Sr. Director of Investor Relations
Mr. Jason B. Daly Esq. Sr. VP, Chief Legal Officer & Corp. Sec.
Mr. Sanjiv Patel Sr. VP of Operations
Dr. Nikunj Patel Head of Ops & Exec. VP of Amneal Pharmaceuticals (India) Pvt Ltd
Mr. Sanjay Kumar Jain Ph.D. Pres of India Operations

Exchange: NYSE

Country: US

Currency: US Dollar ($)

Forward PE: 6.2972
Trailing PE: 220
Price-to-Book MRQ: 1.1865
Price-to-Sales TTM: 0.3221
IPO Date: 2009-01-15
Fiscal Year End: December
Full Time Employees: 7000
Back to stocks